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1. Abstract 
Myxoid liposarcoma (MLS) is a rare soft-tissue tumor. An important oncogenic factor driving 
the tumor is abnormal proliferative signals through tyrosine kinases. Tyrosine kinase 
inhibitors have been tested as a treatment, but with little effect. An explanation to this might 
be that different tyrosine kinases can form heterodimers and autophosphorylate each other in 
the cytoplasm of MLS cells, sustaining a proliferative signal. A protein that can promote this 
autoactivation process is Heat shock protein 90 (HSP90). HSP90 is a chaperone, a protein 
involved in modifying misfolded proteins and helping protein complex formation. In tumors, 
HSP90 has been linked with phosphorylation of tyrosine kinases and promotion of cell 
proliferation. HSP90 inhibition has been developed as a method to treat cancer. Experiments 
on mice with MLS and on MLS cell lines have shown that HSP90 inhibition has great 
potential. The aim of this study was to elucidate the mechanism of HSP90 inhibitions in MLS 
and the connection to tyrosine kinase signaling, using an HSP90 inhibitor called 17-DMAG. 
Cultured tumor cells have been analyzed regarding to cell proliferation, expression of target 
proteins and signaling pathways. The results showed that 17-DMAG diluted in cell medium 
with 5 % FBS reduced cell proliferation in MLS cell lines. Fibroblasts, used as control cells, 
were not affected by the drug. Untreated fibroblasts had in general a significantly lower 
expression of 17-DMAG target proteins than untreated tumor cells. In MLS cell lines, protein 
quantification showed that activation of tyrosine kinase receptors RET and ErbB3 were 
reduced after addition of the drug. This indicates that 17-DMAG specifically affects cells 
dependent on tyrosine kinase signaling, decreasing proliferation and causing cell death. 
Tyrosine kinase signaling is an important oncogenic factor in myxoid liposarcoma, suggesting 
that HSP90 inhibition is a possible method for treatment of tumor cells without affecting 
normal tissue. 
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2. Background 
2.1 Cancer 
Cancer is one of the biggest health problems in the world, having increased both in incidence 
and in mortality since the middle of the 20
th
 century (1, 2). Estimated life-time probability of 
cancer differs between countries, but is in Sweden approximately 33% and in the US 
approximately 45% (1, 2). Cancer is the second most common cause of death after 
cardiovascular diseases, accounting for every fourth death in both Sweden and the US.  
Cancer is a collective term for malignant tumors. Malignant tumors can either originate from 
epithelial cells or mesenchymal tissue. Malignant tumors originating from epithelial cells are 
referred to as carcinomas, whereas malignant tumors originating from mesenchymal tissue are 
referred to as sarcomas. Cancer is a group of diseases caused by an abnormal proliferation of 
cells. The most common cancers are prostatic cancer, breast cancer, skin cancer, lung cancer 
and colon cancer (fig.1). All these malignant tumors are carcinomas. Sarcomas, on the other 
hand, are very rare tumors, accounting for less than 1 % of all tumors. 
2.2 Sarcomas 
Approximately 350 new cases of Sarcomas are diagnosed in Sweden every year, according to 
Cancerfonden and Socialstyrelsen (2). One quarter of these tumors originate from the bones, 
whereas three quarters of the tumors originate from soft-tissue, such as fibrous tissue, 
muscles, nerves, blood vessels and lymphatic vessels (2). Liposarcomas account for 20 % of 
all sarcomas (3), making them the most common form of all mesenchymal tumors. The five 
year disease-specific survival rate of liposarcoma is approximately 77 % (4) , but depends on 
the histological subgroup (3). 
The three main groups of liposarcomas are well-differentiated liposarcoma, pleomorphic 
liposarcomas and Round-cell/Myxoid liposarcoma (Fig.1). These can be further divided into 
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histological subtypes. The different groups of liposarcomas have some histological and 
genetic differences, as well as diversity in incidence, localization and survival rate (3). 
Myxoid liposarcoma (MLS) is the tumor that we will focus on in this paper.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 Diagram showing the most common forms of malignant tumors. Myxoid liposarcoma (MLS) is a very rare tumor, 
belonging to the sarcoma group of tumors (2) 
 
2.3 Myxoid liposarcoma 
Myxoid liposarcoma (MLS) is the second most common liposarcoma, representing 
approximately 30-35 % of all the cases. It occurs most frequently in patients between 35-55 
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years old. The tumors grow deep down in muscles, under the muscle fascia, and the majority 
of tumors occur in the thighs (3).  Histologically, MLS contain few, spindle-shaped cells, on a 
myxoid background. Adipocyte precursor cells, lipoblast are often present; they are 
monovacuolated and located in perivascular areas. The tumors are often hypocellular with 
hypercellular areas, where the cells are more round-shaped (Fig.2). Some tumors are 
dominated by these hypercellular areas and they are referred to as round-cell liposarcoma 
(RCLS). In the old tumor-classification from WHO, RCLS and MLS are seen as two different 
subgroups of liposarcoma. Nowadays, it is believed that RCLS is a more aggressive form of 
MLS, since a transition from hypocellular to hypercellular tumors is common in MLS. 
Cytogenetic profiling also confirms this model, since MLS and RCLS share the same 
cytogenetic profile (3).  
Fig.2 Histological sections of MLS. Left picture show the spindle-shaped cells on a myxoid background. Right picture shows 
a transition from a hypocellular to a hypercellular tumor (3). 
 
The five year survival rate (5-YSR) of MLS is 70 %. If only considering the localized pure 
myxoid MLS, 5-YSR is 93 %, whereas the more aggressive subgroup RCLS has a 20 % 5-
YSR (3, 5). Metastatic progression of pure myxoid MLS is rare but occurs in 10-20 % of the 
cases (6). Metastases are more common in RCLS. Some common locations for metastases are 
the retroperitoneum, peritoneum, peritoneal cavity, axilla, skeleton and the lungs (5-7). 
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2.3.1 Treatment for myxoid liposarcoma 
The most common treatment for liposarcomas is surgery, often in combination with radiation 
to reduce the risk of local recurrence. Chemotherapy is used as a treatment for tumors larger 
than 10 cm and when metastasis has occurred (5). The most commonly used drug in MLS is 
doxorubicin, belonging to the antracycline group (8-10). It acts by inhibiting topoisomerase 2, 
thus blocking replication. Doxorubicin is being used as a mono-therapy drug. Combination 
with contumumab, a monoclonal antibody against death receptor 5 has been tried without any 
increased efficiency (11).  
The response rate of doxorubicin is around 20-30 % and shows an objective diminution in 
tumor size (12, 13). Treatment with doxorubicin is associated with a progression free survival 
of 3-4 months. After this period, the tumors get resistant to the drug and the patient face a 
quick progression of the disease. No effect on overall survival rate has been seen, and toxicity 
is high with side effects such as neutropenia, systolic dysfunction, mucositis and alopecia (8). 
Another drug that is currently used as second line therapy is trabectedin. Trabectedin is a 
DNA minor groove alkylator that causes cell cycle arrest in S and G2 phase. It shows an 
overall survival rate of 21 months, in comparison to 12-14 months in untreated controls (14). 
The most serious side effects of this drug are leukocytopenia and thrombocytopenia. The most 
common side effects are nausea, fatigue, diarrhea, constipation and anemia (14). 
A third drug that has been used against MLS, mostly in combination with doxorubicin, is 
ifosfamide. Ifosfamide is an alkylating drug with a mono-therapy response rate around 10-20 
% (12, 15). Combining ifosfamide and doxorubicin significantly increases progression free 
survival rate (12). There is no other cytostatic with good effect against metastatic MLS at the 
market today. 
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2.3.2 Cytogenetic 
Human sarcomas are generally known for their genomic instability, meaning that the tumors 
have a complex and unbalanced karyotype. The heterogeneity between tumors of the same 
type is vast and usually there is not a single mutation that drives the oncogenesis (16).  
MLS on the other hand are genetically stable and characterized by a single chromosomal 
translocation between chromosome 12 and 16, t(12;16)(q13;p11) (17). This translocation is 
prevalent in more than 90 % of all MLS and creates a fusion between the protein FUS (also 
called TLS and GADD153) and DDIT3 (also known as CHOP), resulting in a fusion protein 
called FUSDDIT3 (TLSCHOP). FUS is an RNA-binding protein, which is involved in 
transcriptional activation. It belongs to the FET-group of proteins, including FUS, EWSR1 
and TAF15, which are all important genes in tumor specific translocations. DDIT3 is a stress-
induced protein that is involved in cell-stress and apoptosis. The fusion protein FUSDDIT3 is 
an abnormal transcription factor believed to be important for the tumor development, 
affecting well-known downstream targets such as NFKB, IL6, C/EBP ß, IL-8, p53 and 
MDM2 (3, 18, 19). 
2.4 Tyrosine kinase receptors in MLS 
It has been shown that increased tyrosine kinase receptor activity is an important oncogenic 
factor in MLS (20). Tyrosine kinase receptors are receptors that exist in several cell types in 
our body. Their normal function is to bind their ligand and dimerize with another tyrosine 
kinase receptor. Upon dimerization, a kinase-activity is started, which causes phosphorylation 
and formation of large protein complexes around the receptors. This starts a signal cascade 
that ultimately generates a response in the cells. Typically, they are involved in cell 
proliferation, differentiation, migration and cell cycle control (21). 
Overactivity of tyrosine kinase receptors is common in tumors, and can occur because of 
activating point mutations, autocrine stimulation, receptor overexpression or chromosomal 
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rearrangement (21). These mutations cause the tyrosine kinase receptor to remain in a 
phosphorylated state and sustain abnormal cell proliferation stimulating signals. 
In MLS, it has been reported that multiple tyrosine kinase receptors have increased activity, 
among them RET, EGFR, ErbB3 and Flt1.  It has also been shown that different tyrosine 
kinase receptors can cross-talk and activate each other by heterodimerization (20). 
Unpublished material from Åman group, confirmed that MLS cell lines have a higher 
expression of RET and EGFR than a fibroblast control cell line. Experiments comparing MLS 
cell lines and the fibroblast cell line, regarding expression of ErbB3 and FLT1 have not been 
done. 
RET encodes a tyrosine kinase receptor that stimulates cell proliferation. Overexpression of 
RET is linked with different forms of human tumors, most commonly the multiple endocrine 
neoplasia type 2 syndrome (MEN2-syndrome) causing medullary thyroid carcinoma, 
pheochromocytoma and primary hyperparathyroidism. The four natural ligands for RET are 
called PSPN, GDNF, NRTN and ARTN, and among them, PSPN is expressed by MLS cells 
(22).  
EGFR is also a cell surface tyrosine kinase receptor that stimulates cell proliferation. It 
belongs to the ErbB family of receptor tyrosine kinases. Overexpression of this protein is 
linked with cancer (lung cancer, anal cancer, glioblastoma multiforme). EGFR is activated by 
a number of ligands, among them EGF and TGF-α. Upon activation, EGFR creates 
homodimers with other EGFR, or heterodimers with other tyrosine kinase receptors from the 
ErbB family (23) . 
ErbB3 is a cellular receptor also belonging to the ErbB family of receptor tyrosine kinases. 
This receptor does not have any kinase domain on its own, and upon activation, is required to 
form heterodimers with other members in the ErbB family to convey its signal (24). The 
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ligands of ErbB3 are called neuregulin 1 and 2. ErbB3 is often seen in tumors that express 
high levels of ErbB2, but has not been proved to cause tumors on its own. ErbB3 helps 
activating the phosphatidylinositol 3-kinase pathway (PI3K), a famous pathway involved in 
cell growth, cell proliferation, cell migration and tumor development (25, 26). 
2.5 Tyrosine kinase receptor inhibition in MLS 
Unpublished experiments made by Åman group, showed that RET is phosphorylated, hence 
activated in MLS cell lines and human tumors. DNA sequencing showed that the protein is 
not mutated. When treating MLS cell lines with RET tyrosine kinase receptor specific 
antibody vandetanib, no effect on phosphorylation or cell viability could be seen.  This 
suggests that RET can be activated by a ligand independent mechanism. 
It is known that activated EGFR can phosphorylate and activate RET by heterodimerization in 
the cytoplasm in thyroid cancer cells (27). ErbB3 and EGFR are very similar in their function 
and in MLS, ErbB3 has been shown to dimerize with RET. Nevertheless, inhibiting 
antibodies against tyrosine kinase receptors ErbB3 and EGFR also fail to reduce 
phosphorylation of RET, shows unpublished material from Åman group. 
Heterodimerization of different tyrosine kinase receptors might be an explanation for this 
tyrosine kinase receptor inhibitor resistance. Blocking one tyrosine kinase receptor pathway 
may not be enough to block this autophosphorylation process and therefore does not reduce 
the level of phosphorylated RET.  
2.6 Heat Shock Protein 90 
A protein that have RET, ErbB3 and EGFR as target proteins and that might be of interest in 
the heterodimerization process described in the previous section is Heat shock protein 90 
(HSP90). HSP90 is a chaperone, a protein being involved in protein folding, modification and 
complex formation. It helps newly synthesized proteins to obtain their biologically active 
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structure and creates protein complexes, while helping misfolded proteins to be repaired or 
degraded (28). HSP90 corresponds to 1-3 % of the cellular total protein load, has more than 
20 co-chaperones modifying its own activity and has an effect on more than 400 client 
proteins (29). In cancer, HSP90 is believed to maintain cell proliferation pathways by 
preserving important proteins for cell signaling. HSP90 has also been linked to some other 
important hallmarks of cancer such as overcoming environmental stress, reduce nutrient and 
oxygen demands, prevention of destruction by the immune system, angiogenesis and 
promotion of metastasis (28). Inhibiting HSP90 could therefore have an effect on tumor cells 
in multiple aspects. 
2.7 HSP90 inhibition 
HSP 90 inhibition has become a very interesting mechanism for antitumor drug development 
and at least 17 HSP90 inhibitors are available on the market today (28, 29). It has mostly been 
tested against advanced tumors of high grade such as breast cancer, prostate cancer, 
melanoma, multiple melanoma and ovarian cancer (28). The earliest versions of HSP90 
inhibitors have not proven to be very efficient, and had a very common side effect in liver 
toxicity. Recently, a number of new HSP90 inhibitors have emerged on the market with 
greater potential and less side effects (30). 
2.7.1  17-AAG 
Unpublished experiments on MLS cell lines with an HSP90 inhibitor called tanespimycin (17-
AAG, 17-allylamino-17-demethoxygeldanamycin), have been done by Åman group. 17-AAG 
was one of the first HSP90 inhibitors on the market. The results were promising and showed 
that HSP90 inhibition diminished MLS cell lines while having little effect on control cell lines 
such as fibroblasts. The problem with this drug is that it is not water soluble, making it hard to 
infuse in animals. It also has a major side effect in liver toxicity, making it hard to increase 
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the dose to optimal treatment dose (28). Since the clinical potential was low, no further 
experiments with this drug on MLS cell lines have been done.  
2.7.2  17-DMAG 
Alvespimycin, (17-DMAG, 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin) 
belongs to a newer generation of HSP90 inhibitors. This drug is more water soluble and 
potent than its precursor 17-AAG. Because of its water solubility and improved 
pharmacodynamics, it has fewer problems with liver toxicity. It has been documented to have 
contributed to a complete response in a patient with castration resistant prostate cancer, 
verified with CT and PSA (31). In other studies, it has shown a partial response against breast 
cancer.(32) 
Phase 1 trials have shown that the drug is tolerable up to a maximum dose of 21 mg/m
2
 
infused twice a week with fatigue, nausea, musculoskeletal pain as major side effects (33).  
Unpublished experiments on MLS cell lines, treated with 17-DMAG, have been done by 
Åman group. In cell culture, a drug titration curve of 17-DMAG was performed on MLS cell 
lines, showing that 30 nM of the drug is effective for inhibiting cell proliferation (Fig.3). In 
2013, experiments with injections of 17-DMAG in immunodeficient xenograft mice 
incorporated with human MLS were started. Preliminary results indicated that treatment with 
17-DMAG reduced tumor surface area up to 60 %, without any obvious side effects. 
Histological examinations of tumors showed reduction in cell number, apoptosis, necrosis and 
vessel bleedings (fig.4).  
These results were of immense interest and have given rise to the initiative of a phase 2 trial 
with a HSP90 inhibitor against MLS. The exact mechanism of action, optimal treatment 
conditions and treatment interval for this drug against MLS are still not fully investigated, and 
more research is required to fully understand the potential of HSP90 inhibition. 
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 Fig.3. Three of four MLS cell lines have a sufficient response of around 30 nM 17-DMAG after 72 hours. DL221 does not 
seem to be sensitive to 17-DMAG (Unpublished material from Åman group) 
0 
0.5 
1 
1.5 
0  250  125  63  31  16  8  4  2  N
o
rm
al
iz
e
d
 c
e
ll 
d
e
n
si
ty
 
17-DMAG concentration (nM) 
MLS 1765 
Fig.4.Histological examination of tumors from xenograft mice show reduced cell number, apoptosis, necrosis and 
vessel rupture after only one week of 17-DMAG treatment (Unpublished material from Åman group.) 
 
Control 17-DMAG (1 week) 
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2.8 Aim 
The aim of this project was to elucidate the effect of 17-DMAG on MLS cells and its 
connection to expression and function of tyrosine kinase receptors RET, ErbB3 and EGFR.  
16 
 
3. Material and methods 
 
3.1 Summary of data collection and methods of analysis 
Myxoid liposarcoma cells have been provided from cell culturing. Cells have been analyzed 
according to expression of target proteins, RNA level, viability and proliferative capacity.  
17-DMAG (Alvespimycin) is produced by Bristol-Myers. It is water soluble and upon arrival 
dissolved in physiological sodium-, chloride- and phosphate buffer to 1 mg/ml (1,62 mM). 
For the experiments, the drug has been diluted in cell medium, with or without serum, to a 
final concentration of 10 or 30 nM. 
3.2 Methods 
3.2.1 Cell culture 
6 cell lines have been used; MLS cell lines Avory, 1765, 402 and DL221, fibrosarcoma cell 
line HT1080 and fibroblast cell line F470. The cell lines Avory, 1765, 402 and HT1080 are 
fast growing cell lines, whereas DL221 and F470 grow slowly. All cells have been cultured in 
RPMI 1640 GlutaMAX, with addition of 5 % fetal bovine serum and 1 % PEST (to a final 
concentration of 100 U/ml of penicillin and 100 µg/ml streptomycin). The cell medium 
contains 2 mM of L-Alanyl-Glutamine and phenol Red as a pH-indicator. 
3.2.2 Cell proliferation assay (Xcelligence) 
To examine cell viability and proliferation after addition of 17-DMAG, Xcelligence cell 
proliferation assay was used. This system measures the impedance of the wells, which is 
correlated to number of cells. When cells die, they round up, hence covering a smaller area. 
In this experiment, cell medium was added to two 16-well E-plates and analyzed in RTCA DP 
culture hood analyzer, to measure background impedance. Then, duplicates of the MLS cell 
lines and the fibroblast cell line were added and incubated in the RTCA DP culture hood for 
24 hours. After that, 10 or 30 nM of 17-DMAG was added and the plates were put back in the 
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RTCA DP culture hood for 160 hours. Impedance measurements were made once every 30 
minutes. For the analysis, data was normalized in excel and the average expression of MLS 
cell lines and the fibroblast control cell line were analyzed in three categories; controls, 10 
nM and 30 nM of 17-DMAG. Time points from approximately every 12 hours were taken and 
the difference between average cell indexes in the different groups was analyzed using Mann-
Whitney U non-parametric test. Each treatment group consists of a total of 8 cell replicates 
from 4 MLS cell lines. 
3.2.3 Manual drug assay analysis 
Cells were cultured in a 96 well plate. After 24 hours, 17-DMAG was added, with or without 
additional factors. After 72 additional hours, the wells were washed with PBS and fixated 
with 4 % formic acid. Evan’s blue, diluted in PBS, was added to all wells to color the cell 
membranes. The wells were then washed with PBS and photographed with a light 
microscope, using the Axiovision software. 
3.2.4 Cell proliferation kit (CyQUANT) 
To measure relative DNA quantity, corresponding to cell numbers, a CyQUANT cell 
proliferation assay kit (Life Technologies) was used. The cells were cultured and treated in 
the same steps as above. After 72 hours, the cell medium was removed and wells were 
washed with PBS. The plate was frozen down in -80
o
C for 25 minutes, thawed at 37
 o
C for 15 
minutes and repeated three times. After that, cell lysis buffer and nucleic acid binding 
CyQUANT GR dye were added and light absorption of the plate was analyzed in a microplate 
reader with emission at 485 nM and detection at 530 nM. The values, corresponding to the 
DNA content, were exported to Excel and normalized in comparison to controls. 
3.2.5 Immunofluorescence 
To visualize expression of target proteins and localization in the cell, immunofluorescence 
technique was used. Cells were transferred to a 4-well objective glass, then different 
concentrations of 17-DMAG were added at appropriate time points. Cells were washed using 
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phosphate buffered saline (PBS), then fixated cells for 5 minutes using 4 % formic acid. After 
additional washes with PBS, primary antibody diluted in block AB-buffer (1 % BSA, 0,5 % 
TritonX in PBS) was added.  
After one hour incubation, wells were washed in PBS and secondary antibody (directed 
against primary antibody), containing a green GFP fluorophore, was added diluted in AB-
buffer with 0,4 % phalloidin (red cytoskeleton color). The cells were washed with PBS and 
blue DAPI DNA stain was added as the cells were fixated on a microscope slide. The slides 
were analyzed using a Zeiss Fluorescence microscope and Axiovision 4.3.2 software. Filters 
for DAPI (blue), Texas red (Red) and GFP (green) were used. The same exposure time was 
used for different wells to be able to quantify the results. 
3.2.6 Western blot 
To further investigate expression of target proteins, Western blot technique was used. Cell 
samples were cultured and treated with 17-DMAG in 6-well plates. Cell samples were 
scraped off using RIPA-buffer with EDTA and phosphatase-inhibitor. Samples were 
centrifuged; supernatant was separated from pellet and then mixed with 4X LDS sample 
buffer. Protein concentration was measured in undiluted samples using BioRad protein Assay. 
Samples were then mixed with Sample reducing agent and the same amounts of samples were 
loaded onto a NuPage 4-12 % Bis-Tris 12 well gel, together with ladder. Electrophoresis was 
done at 200 V for one hour, separating the proteins. Then, a transfer was done at 30 V for 75 
minutes to transfer the proteins from the gel to a PVDF membrane. The membrane was 
washed in Tris-buffered Saline and Tween (TBS-T) and then put in block solution (5 % Skim 
milk powder in TBS-T or 5 % BSA in TBS-T). Primary antibodies were added and the 
membrane was incubated for one hour in room temperature or overnight at 4 degrees. The 
membrane was washed with TBST, and then secondary peroxidase-linked antibody was 
added diluted in block solution. After one hour of incubation, the membrane was washed in 
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TBST and put in West Femto Extended duration substrate. Bands were then detected using a 
GE LAS-4000. 
To detect other target proteins, the membranes were stripped using stripping buffer and 
incubated with new antibodies. GAPDH was used as a loading control to be able to verify the 
total amount of loaded protein. 
To quantify band intensity, Multi-Gauge software was used. Bands were calibrated against 
background and quantified in comparison to loading control. Then samples were normalized 
in comparison to untreated controls to investigate effect of 17-DMAG treatment. Calculations 
were done in Excel. 
3.3 Statistical analysis 
Data are shown as mean values of replicates unless stated differently. Up- and downregulation 
are shown in percent, with p-values when applicable. Analyses were done on Microsoft Excel 
® 2013, IBM SPSS statistics 22 and GraphPad Prism 6. Differences between groups were 
determined using non-parametric Mann-Whitney U and p-values < 0.05 were considered 
significant. 
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Fig.6 Western blot image of ERBB3 expression in 
three MLS cell lines and a fibroblast control cell 
line. F70, The fibroblast cell line has a lower 
expression of ErbB3 
4. Results 
4.1 Expression of tyrosine kinase receptor ErbB3 in untreated cells 
Previous experiments made by Åman group have shown that MLS cell lines contain RET and 
EGFR, whereas fibroblasts do not. To verify the results 
for ErbB3 a western blot with antibodies directed 
against ErbB3 was made. 
The results show that expression of 
ErbB3 is higher in MLS cell lines than in 
fibroblasts (Fig.6). 
 
4.2 Cell proliferation assay on cells treated with 17-DMAG 
To see the effect of 17-DMAG (diluted in serum free cell medium) in MLS cell lines, the cell 
index (referring to cell proliferation) was measured every 30 minutes during 56 hours after 
addition of 17-DMAG. Four MLS cell lines and a fibroblast cell line as control were treated in 
duplicates with 10 and 30 nM of 17-DMAG and compared to untreated controls. Decrease in 
cell proliferation was observed in MLS cell lines Avory and 1765, treated with the drug. In 
contrast, the proliferation rate was unchanged in treated MLS cell lines DL-221, 402 and the 
fibroblast control cell line F470 (Fig.7.). 
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 Fig.7. Cell proliferation assay in four MLS cell lines and a fibrosarcoma cell line. In Avory and 1765 we can see a clear 
effect of the treatment. In DL221, 402 and F470 the drug does not seem to affect the cells. Only data after drug has been 
added is shown. Each sample has been set up in duplicates.  
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Fig.8a Complete image of an immunofluorescence of MLS cell line Avory treated with 30 nM 17-DMAG for 6 hours. 
Top left corner shows blue DAPI nuclear color. Bottom left corner shows red phalloidin actine color. Top right corner 
shows green GFP target protein color (in this case ErbB3) and bottom right corner shows a combined picture of all 
colors. 
4.3 Exploring target proteins using immunofluorescence and Western blot 
To detect effect on target proteins DDIT3, ErbB3, EGFR and RET upon treatment with 17-
DMAG, immunofluorescence was performed. MLS cell line Avory treated with 30 nM 17-
DMAG for 4 and 6 hours was compared with untreated cells.  
All target proteins are detectable to some extent but it is hard to detect any significant 
difference between the control groups and the treated groups (fig.8a-b)  
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 DDIT3 ErbB3 EGFR RET 
 
 
Control 
    
 
 
17-DMAG 30 nM, 
6 h 
    
Fig.8b Immunofluorescence of MLS cell line Avory treated with 30 nM 17-DMAG for 6 hours and compared to 
controls. No difference can be noticed between samples treated for 4 or 6 hours, so only results for 6 hours are 
presented.Target proteins are DDIT3, ERBB3, EGFR and RET. 
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HSP90 ErbB3 
Fig.9 Immunofluorescence of MLS cell line Avory treated 
with 30 nM 17-DMAG for 24 and 48 hours and compared 
to controls. Target proteins are HSP90 and ErbB3. The 
cell amount after 48 hours is extremely high, so results are 
hard to interpret. 
 
Control 
 
24 h 
 
48 h 
To ensure that the effect on target proteins did not occur later, two new plates of the MLS cell 
line Avory, treated with 30 nM of 17-DMAG 
(diluted in serum free cell medium), were set up. 
Antibodies were directed against ErbB3 and 
HSP90, the direct target protein of 17-DMAG. No 
significant difference between treated groups and 
untreated controls was found (fig.9).  
Since no difference between treated and untreated 
groups could be seen, one last immunofluorescence 
with antibodies directed against phosphorylated 
ErbB3 and RET was done. Phosphorylation of 
these proteins corresponds to activation, and a 
downregulation of phosphorylation would 
correspond to fewer activated tyrosine kinase 
receptors. The cells were treated for 16, 24 and 48 
hours and compared to untreated control. There was no difference found between treated and 
untreated groups and results are not presented. 
To be able to quantify the protein levels more precisely, a Western blot was performed. 
Samples were made of MLS cell line Avory treated with 30 nM of 17-DMAG for 4 and 6 
hours and compared to untreated control. The drug was dissolved in cell medium and 
antibodies were directed against ErbB3.  No difference could be seen between treated samples 
and untreated controls and bands have not been quantified (fig.10) 
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Fig.10 Western blot of MLS cell lines Avory treated with 17-DMAG for 4 and 6 
hours. Top band is ErbB3 (148 kDa), bottom band is GAPDH (36 kDa) as loading 
control. No difference can be observed between the different samples. 
 
4.4 Serum seems to mediate 17-DMAG effect 
The absence of drug effect, though animal experiments and previous results have shown its 
presumed existence led us to further investigations of the previous protocols to see if anything 
differed between previous and new experiments. The major difference was that in previous 
experiments the drug had been diluted in cell medium containing 10 % fetal bovine serum. 
Fetal bovine serum contains a high content of proteins, including albumin, growth factors and 
other signal proteins that could mediate an effect. It was also possible that continuous freezing 
and thawing of the drug stock denaturized the drug. 
To test these hypotheses, a 96-well plate with the MLS cell line Avory was set up. Different 
treatment concentrations of 17-DMAG, with and without serum was tested both with the old 
stock solution of 17-DMAG and a stock solution that had never been thawed. Cell confluence 
was observed daily in a light microscope. After 72 hours the cells were fixated, stained with 
nuclear staining and photographed. The results show that serum seems to be a necessary 
factor for the drug to affect the cells (Fig.11). 17-DMAG dissolved in cell medium still does 
not show any significant difference between treated and untreated group. 10 nM of 17-DMAG 
diluted in cell medium with 5 % FBS does not have any effect on the cells whereas 30 nM of 
the drug diluted in cell medium with 5 % FBS causes a decrease in cell density. The results 
were reproducible for both the old and unthawed batch of drug, disproving the theory of any 
difference between the stock solutions. 
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Since serum seems to be an essential factor for 17-DMAG to have effect some of the previous 
experiments were rerun with 17-DMAG dissolved in cell medium with 5 % FBS. 
4.5 New cell proliferation assay 
A new cell proliferation assay was made to see how the cells were affected by 17-DMAG 
diluted in cell medium with serum. Decrease in cell proliferation was now observed in all 
MLS cell lines, whereas the fibroblast cell line was not affected by the drug (Fig.12a-c). 
Avory 17-DMAG 
30 nM (medium) 
Fig.11 Images of tumor cells treated with 17-DMAG diluted in medium or medium with 5 % Fetal bovine serum. It seems that 
17-DMAG diluted in medium does not mediate any effect whereas 30 nM of 17-DMAG diluted in serum does. Results are 
reproducible for both the tested cell lines and for both the unthawed and old batches of drug (results not shown). 
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Fig.12a. Cell proliferation assay on 4 MLS cell lines and a fibroblast cell line indicates that all MLS cell lines are sensitive to 
the drug. Fibroblasts have only been run for 96 hours after addition of the drug. 
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Fig.12b Average of MLS cells treated with 30 nM 17-DMAG have decreased cell index, whereas 10 nM of 17-DMAG does 
not affect the cells. 
 
 
Fig.12c Control MLS cells and cells treated with 30 nM 17-DMAG. Percentage reduction in 30 nM samples indicated below 
time points. P-values calculated with Mann-Whitney U for each time point are highlighted below. 
4.6 Immunofluorescence on cells treated with 30 nM 17-DMAG 
A new immunofluorescence was made to detect any effect on target proteins. The cell 
proliferation data suggested that MLS cell lines Avory and 1765 responded strongest to 17-
DMAG and showed a great decline in cell viability. Therefore, MLS cell line Avory was 
treated for 48 hours and compared to control. Antibodies were used against the target proteins 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
0 22 45 67 89 112 
C
e
ll 
in
d
e
x 
MLS cells 
MLS control 
MLS 10 nM 
MLS 30 nM 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
0 22 45 67 89 112 
C
e
ll 
in
d
e
x 
MLS cells 30 nM 
MLS control 
MLS 30 nM 
-43.5%         -61.1%       -62.8%         -61.6%           -43.4% 
P=0.067      p=0.022        p=0.029      p=0.035        p=0.048 
29 
 
RET and ErbB3. The results are hard to interpret since control wells are extremely confluent 
and few cells have survived 48 hours of treatment. Only Avory controls and cells treated for 
48 hours are presented since additional data did not contribute to the results (fig.13). Neither a 
difference in location, nor a downregulation of target proteins could be verified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.13 Immunofluorescence of MLS cell line Avory treated for 48 hours and compared to control. Reduction of target protein 
expression or change of cellular location cannot be detected.  
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4.7 Western blot on target protein after addition of 30 nM 17-DMAG 
To be able to verify a reduction of target proteins, a Western blot with similar samples was 
performed. Antibodies against EGFR, ErbB3, RET, pEGFR, pErbB3 and pRET have been 
tested (fig.14). Band signal ratio between target protein and loading control was measured. 
(table.2). Downregulation of pRET and pErbB3 was observed after addition of 30 nM 17-
DMAG. RET and ErbB3 were possibly downregulated, whereas EGFR and pEGFR seemed 
to be slightly upregulated (Fig.14). 
  
Cell index at different time points in comparison to controls 
Cell type Avory 1765 
Conc. 10 nM 30 nM 10 nM 30 nM 
Time  c 6h 24h 48h c 6h 24h 48h c 6h 24h 48h c 6h 24h 48h 
RET 1 1.00 1.13 1.24 1 0.75 0.56 0.77 1 0.75 1.44 2.91 1 0.77 0.08 0.03 
pRET 1 2.47 1.10 2.42 1 0.53 0.32 0.21 1 1.43 0.34 0.20 1 0.52 0.20 0.13 
ErbB3 1 2.63 2.22 2.10 1 0.60 0.55 0.29 1 0.89 1.65 1.59 1 0.68 0.93 0.30 
pErbB3 1 2.02 0.45 0.38 1 0.84 0.40 0.22 - - - - - - - - 
EGFR 1 0.72 1.33 0.69 1 0.76 1.06 0.92 - - - - - - - - 
pEGFR 1 1.23 0.70 0.56 1 0.95 1.01 1.29 1 1.20 0.60 0.59 1 1.65 1.43 2.87 
Table.2. Quantification index of MLS cells Avory and 1765 treated with 17-DMAG. Results are based on quantification data. EGFR and 
pErbB3 have only been tested with Avory membrane. 
31 
 
0 
1 
2 
3 
4 
control 6 h 24 h 48 h 
RET quantification 
(Avory) 
10 nM 30 nM 
0 
1 
2 
3 
4 
control 6 h 24 h 48 h 
RET quantification 
(1765) 
10 nM 30 nM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RET 
GAPDH 
 
1
0
 n
M
 c
o
n
tr
o
l 
1
0
 n
M
 6
h
 
1
0
 n
M
 2
4
 h
 
1
0
 n
M
 4
8
 h
  
3
0
 n
M
 c
o
n
tr
o
l 
3
0
 n
M
 6
h
 
3
0
 n
M
 2
4
 h
 
3
0
 n
M
 4
8
 h
  
Avory 
1
0
 n
M
 c
o
n
tr
o
l 
1
0
 n
M
 6
h
 
1
0
 n
M
 2
4
 h
 
1
0
 n
M
 4
8
 h
  
3
0
 n
M
 c
o
n
tr
o
l 
3
0
 n
M
 6
h
 
3
0
 n
M
 2
4
 h
 
3
0
 n
M
 4
8
 h
  
1765 
pRET 
GAPDH 
 
1
0
 n
M
 c
o
n
tr
o
l 
1
0
 n
M
 6
h
 
1
0
 n
M
 2
4
 h
 
1
0
 n
M
 4
8
 h
  
3
0
 n
M
 c
o
n
tr
o
l 
3
0
 n
M
 6
h
 
3
0
 n
M
 2
4
 h
 
3
0
 n
M
 4
8
 h
  
Avory 
1
0
 n
M
 c
o
n
tr
o
l 
1
0
 n
M
 6
h
 
1
0
 n
M
 2
4
 h
 
1
0
 n
M
 4
8
 h
  
3
0
 n
M
 c
o
n
tr
o
l 
3
0
 n
M
 6
h
 
3
0
 n
M
 2
4
 h
 
3
0
 n
M
 4
8
 h
  
1765 
32 
 
 
 
 
  
ErbB3 
GAPDH 
 
1
0
 n
M
 c
o
n
tr
o
l 
1
0
 n
M
 6
h
 
1
0
 n
M
 2
4
 h
 
1
0
 n
M
 4
8
 h
  
3
0
 n
M
 c
o
n
tr
o
l 
3
0
 n
M
 6
h
 
3
0
 n
M
 2
4
 h
 
3
0
 n
M
 4
8
 h
  
Avory 
1
0
 n
M
 c
o
n
tr
o
l 
1
0
 n
M
 6
h
 
1
0
 n
M
 2
4
 h
 
1
0
 n
M
 4
8
 h
  
3
0
 n
M
 c
o
n
tr
o
l 
3
0
 n
M
 6
h
 
3
0
 n
M
 2
4
 h
 
3
0
 n
M
 4
8
 h
  
1765 
pErbB3 
GAPDH 
 
1
0
 n
M
 c
o
n
tr
o
l 
1
0
 n
M
 6
h
 
1
0
 n
M
 2
4
 h
 
1
0
 n
M
 4
8
 h
  
3
0
 n
M
 c
o
n
tr
o
l 
3
0
 n
M
 6
h
 
3
0
 n
M
 2
4
 h
 
3
0
 n
M
 4
8
 h
  
Avory 
EGFR 
GAPDH 
 
1
0
 n
M
 c
o
n
tr
o
l 
1
0
 n
M
 6
h
 
1
0
 n
M
 2
4
 h
 
1
0
 n
M
 4
8
 h
  
3
0
 n
M
 c
o
n
tr
o
l 
3
0
 n
M
 6
h
 
3
0
 n
M
 2
4
 h
 
3
0
 n
M
 4
8
 h
  
Avory 
33 
 
 
 
 
  
Fig.14. Western blot membranes and quantification in comparison to loading control (GAPDH) and normalized to control sample. Tested 
target proteins are RET (128 kDa), pRET (175 kDa), ErbB3 (148 kDa), pErbB3 (210 kDa), EGFR (134 kDa) and pEGFR (175 kDa). Most 
target proteins are tested on both Avory and 1765 membranes, pErbB3 and EGFR are only tested on Avory membrane. Target proteins pRET 
and pErbB3 seem to be downregulated by 30 nM 17-DMAG. RET and ErbB3 are possibly downregulated, whereas EGFR and pEGFR seem 
to be slightly upregulated. 
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4.8 17-DMAG in cells cultured with growth factors and interleukins 
Since serum contains high levels of growth factors, cytokines and other proteins, we wanted 
to examine if any of these proteins were the reason for the drug to have effect when diluted in 
serum.  
To examine this, cells were cultured in serum-free conditions in a 96-well plate and different 
combinations of factors with or without 30 nM 17-DMAG were added. Some of the factors 
are known to affect pathways regulated by HSP90, such as EGF (MAPK- and PI3K-pathway) 
(34), IL6, oncostatin, TGF-ß (NFkB and JAK/STAT-pathway) (35) and IGF-1 (PI3K-
pathways) (35). Some others are highly expressed in serum, such as FGF, NGF, HGF and 
VEGF. This experiment indicated that some of the factors might have a small effect on 
cellular morphology, but these differences are very subtle and rather subjective. The effects 
on viability and growth arrest are easier to objectify visually. In this experiment it seems that 
IL6, IGF-1 and TGF-ß have an effect on the cells and cause reduced cell proliferation (fig.15). 
 
 
 
 
 
 
 
 
 
1765 IL6 30 nM 1765 HGF 30 nM 1765 EGF 30 nM  
1765 FGF control  1765 HGF control 1765 IL6 control 
1765 FGF 30 nM 
1765 EGF control 
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4.9 Using a CyQUANT assay to verify the effect of serum and growth factors 
To verify and quantify these results, a cell proliferation assay was used. Cell lines Avory and 
1765 were cultured and treated with 17-DMAG in different conditions (Fig.16a-b). The 
results verify that serum seems to be required for an effect and that IGF-1 and IL6 with 30 nM 
17-DMAG decreased the total number of cells in both cell lines. TGF-β with 30 nM 17-
DMAG also reduced the cell number, but to a lower extent. 
 
1765 IGF-1 30 nM 1765 VEGF 30 nM 1765 NGF 30 nM 
1765 NGF control 1765 VEGF control 1765 IGF-1 control 1765 TGF-β control 
1765 TGF-β 30 nM 
Fig.15 Cultured cells treated with different factors, with or without 17-DMAG. IL6, IGF-1 and TGF-β seem to 
potentiate the effect of 17-DMAG. 
 
eated cells. 
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Fig.16a Measuring DNA content in cultured wells using a CyQUANT assay indicates that 17-DMAG diluted in cell medium 
with serum is required for the drug to have an effect. Data is normalized to controls. 
 Fig.16b Measuring DNA content in cultured wells using a CyQUANT assay indicates that IL6 and IGF-1 in combination 
with 30 nM 17-DMAG decrease cell numbers in both Avory and 1765. TGF-β decreases cell number to a smaller extent. 
Data has been normalized to control cells of each factor. 
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5. Discussion 
Inhibiting HSP90 is a quite novel anti-tumor strategy, where in rare cases effect has been 
reported on castration resistant prostate cancer. Phase 2 trials with different HSP90 inhibitors 
have been performed, but have not in general shown any major effects (31, 36). 
When it comes to myxoid liposarcoma and other soft-tissue tumors, treatment with 
chemotherapy is sparse and mainly used when metastases have occurred. Only three drugs, 
doxorubicin, ifosfamid and trabectidin are registered for MLS and their effect is limited (12). 
This indicates a great need for novel treatment strategies, where HSP90 inhibition seems to be 
an interesting option. 
In this paper, data has been presented indicating that 17-DMAG has potential treatment effect 
against cultured MLS cell lines. I have showed that some important target proteins of HSP90 
and important signal pathways for maintaining a proliferative capacity in MLS are affected by 
the drug. The most prominent effect of HSP90 inhibition is the decrease in RET and ErbB3 
receptor tyrosine kinase activation. 
MLS cell lines Avory, 402 and 1765 are sensitive to HSP90 inhibition, showed by rapid 
decrease in cell proliferation after addition of the drug. Concerning MLS cell line DL221, 
HSP90 inhibition seems to have a delayed effect. What is unique with DL221 is that it grows 
slower that the other cell lines. DL221 also has a different isoform of the tumor specific 
fusion protein FUSDDIT3, and a p53 mutation, with a loss of function of the tumor 
suppressor attributes of this protein, causing multiple secondary mutations. Any of these 
differences might explain the delayed drug effect but more experiments are needed to verify 
this. 
The MLS cell lines 402 and 1765 started to proliferate again after a couple of days’ drug 
exposition (fig.12a). We hypothesized that this was either because of development of drug 
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resistance or because the drug had been metabolized. After 100 hours, we added more serum 
and 17-DMAG in the wells to see how the tumor cells would react (results not shown). The 
cells quickly started to die, indicating that they were still sensitive to the drug. 
It seems that cell lines that express tyrosine kinases are sensitive to HSP90 inhibition. MLS 
cell lines 1765, 402 and Avory that contain high levels of RET, ErbB3 and EGFR are 
responsive to the drug, whereas fibroblasts with a low expression of tyrosine kinases are more 
resistant. Previous studies have reported that cell lines that are signaling through pathways 
affected by HSP90 are much more sensitive to HSP90 inhibition (28, 35), and it is likely that 
tyrosine kinase dependency is a key factor in HSP90 sensitivity.  It would be interesting to see 
if MLS cell line DL221 expresses RET, ErbB3 and EGFR. If not, it is possible that signaling 
through tyrosine kinases is not the major tumor driving factor in DL221, explaining the lower 
drug effect. 
Interestingly, serum seems to be necessary for the efficiency of 17-DMAG. An explanation to 
this could be the presence of different growth factors and interleukins in serum, which might 
be needed for the effect. The fact that HSP90 has increased effect when stimulating signaling 
pathways targeted by HPS90 has been confirmed in multiple myeloma by Lin et al, 2012 (35). 
Finding and activating pathways that are regulated by HSP90 might consequently be a key to 
successful HSP90 treatment (35). Results from this study indicated that IL6, IGF-1and to a 
lesser extent TGF-β, potentiated 17-DMAG efficiency in serum free conditions. 
Another potential theory about the serum effect might be that serum contains ions that 
interacts with 17-DMAG, causing a precipitate that falls down to the bottom of the well, 
closer to the cultured cells. That is less likely since we have noticed an in-vivo effect of 17-
DMAG in xenograft mice. 
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The molecular mechanism of HSP90 is largely unknown. However, it has been showed that 
HSP90 scaffolds different tyrosine kinase receptors to promote a process of 
heterodimerization and autophosphorylation. It is also possible that HSP90 itself helps 
phosphorylating tyrosine kinases, or prevents breakdown of these proteins once activated. 
Previous research has shown that all tyrosine kinase receptors tested in this paper are target 
proteins of HSP90 (37-39). It has been shown that RET and EGFR can dimerize (27)  and 
experiments from Åman group using a PLA assay show that RET and ErbB3 are co-localized 
in MLS cell lines. It is hard to prove how HSP90 acts in detail, but one mode of action 
proposed in this study, could be that HSP90 inhibition leads to a reduction of phosphorylated 
pRET and pErbB3. Lower pRET and pErbB3 suggest a lower tyrosine kinase signaling, 
which in turn results in lower proliferation signals. RET and ErbB3 seem to be slightly 
downregulated as well, but more experiments need to be done to confirm this. On the other 
hand, both EGFR and pEGFR seem to be slightly upregulated in my results, which does not 
correspond to previous research on the HSP90 inhibitor Geldanamycin (38). The upregulation 
of EGFR and pEGFR could possibly indicate some kind of negative feedback process, where 
EGFR and pEGFR are upregulated to try to sustain a pathway necessary for tumor cell 
vitality. EGFR and pEGFR are said to be highly expressed in MLS cell lines, but in my 
experiments it seems that they are lowly expressed. To verify the effect of EGFR and pEGFR, 
we should do more experiments with other antibodies. 
5.1 On-going experiments 
To more precisely examine the genes that are up- and downregulated in different cell lines 
when treated with 17-DMAG I have collected samples for treated and untreated cells and sent 
them for a micro-array, which is a mass-analysis of what gene pathways that are active. With 
this material we plan to analyze the gene profile of different cell lines with and without the 
drug and see if there are some activated genes that may cause a mechanism for lower drug 
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effect in MLS cell line DL-221. This information will be used for further experiments where 
we will use single-cell PCR to try to find subpopulations within a cell population. Analyzing 
single-cells would give a better understanding on why some cells are more aggressive than 
others and why some cells survive different kinds of therapy. In the future, this may give us 
information on how to individualize cancer treatment depending on the cell population and 
active molecular pathways in a patient’s tumor cells. 
5.2 Methodological considerations 
My results are based on a variety of different methods. This makes it possible to show the 
effect of HSP90 inhibition from different aspects.  The disadvantage of this is that my results 
are not extremely statistically significant. 
Research on cultured tumor cells is tricky since cultured cells also do not behave like tumor 
cells in our body. Concerning our MLS cell lines, they have been immortalized using a SV-40 
virus that might affect the cellular response. Also, since you put the drug directly in the 
medium, you are sure that almost all the cells are exposed to the drug. In the human body, the 
bioavailability of the drug to the cells is lower and other factors such as drug metabolism in 
the liver, tumor suppressing effect of the immune system and a higher degree of drug 
resistance will affect the treatment effect. Therefore, these experiments cannot verify any 
treatment effect in vivo. 
From my findings, I cannot tell if the target proteins change location from the nucleus to the 
cytoplasm. Immunofluorescence results were in general hard to interpret so my conclusions 
are drawn from my results on Western blot. Western blot is a very good method to see if 
proteins are expressed or not, but unfortunately it is not a very secure method to quantify 
expression of target proteins. As my quantification results show, RET, ErbB3, pRet and 
pErbB3 are downregulated by 17-DMAG treatment. When looking at the membranes, it is 
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clear that pRET and pErbB3 are downregulated, whereas the effect of RET and ErbB3 can be 
contributed to the loading control. To verify these results, more Western blots should be done. 
The Xcelligence system is a great system to measure cell proliferation and drug response. 
Already in the first experiments, MLS cell lines Avory and 1765 were sensitive to 17-DMAG, 
although diluted in cell medium. This is probably because we mistakenly only used one tenth 
of the cells recommended for this experiment. In lower cell numbers it seems that cells might 
be sensitive to 17-DMAG, even if serum is not added. 
Since all MLS cell lines were affected to some extent in the last Xcelligence assay, I decided 
to merge the data and to analyze all the MLS cell lines in three groups. Doing this gave me 
more replicates in each group to analyze, making it possible to show statistical correlation in 
between different treatment groups. The difference in cell index between groups could then be 
analyzed using a non-parametric Whitney Mann-U test. This might not be a correct method of 
comparing samples, since all MLS cell lines respond individually to the drug. A better method 
would be to run new experiments with more replicates of each treatment group for each cell 
line and analyze each cell line individually. Unfortunately, this would have been too time-
consuming for this project. 
Previous results have indicated that adding an HSP90 inhibitor with different factors can 
potentiate the drug effect. The results are not always coherent, and no results have been 
presented about MLS cell lines. Culturing cells and taking images is not the best method to 
show how many cells remain after addition of drug with different factors, since only one part 
of one of three replicates is shown in the image. Using a CyQUANT assay to measure DNA 
amount in treated and untreated wells made it possible to quantify the average drug effect in 
the different replicates. I have normalized each factor group with the untreated control of 
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respective factor, which I believe is the best way of showing how the drug is potentiated by 
the factor. 
5.3 Limitations 
Even though 17-DMAG seems to be a potential MLS treatment, it is hard to draw any 
conclusion from experiments on cultured cell lines and Xenograft cells. Side effects, different 
response in human and mice, pharmacokinetic complications and drug resistance are only a 
few of the problems that one may face in human tumor therapy. An example of this is the 
drug 17-AAG that showed great potential in cultured tumor cells, but problems with poor 
water solubility, drug administration, liver toxicity and drug resistance were only a few of the 
complications. Toxicity problems have occurred with 17-DMAG as well, but to a smaller 
extent (30). Recently, some new HSP90 inhibitors have been released on the market. They are 
so called small molecule inhibitors and have a more effective blockage of different isoforms 
of HSP90. Two new HSP90 inhibitors called NVP-AUY922 and NVP-HSP990 have shown 
great potential against prostatic cancer (30, 40). 
In this paper I have only studied the effect on three tyrosine kinase receptors. There are 
approximately 20 tyrosine kinase classes with plenty of receptors that need to be further 
investigated. One receptor that has already shown some interesting results in MLS is the Flt1-
receptor, responding to VEGF-β. We also need to further examine the expression of ligands, 
since it is known that the tumors can produce their own ligands, activating themselves in 
autocrine loops. By mapping the tyrosine kinase receptors and ligands that are active in the 
different tumors, one can get a better clue of the autocrine loops that are present. 
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6. Conclusion and implications 
Tyrosine kinase signaling is an important oncogenic factor in MLS, suggesting that HSP90 
inhibition is a possible method for treatment. Our results indicate that 30 nM of 17-DMAG 
specifically affects cells dependent on tyrosine kinase signaling, decreasing proliferation and 
causing cell death 
Even if 17-DMAG does not become a new therapy for MLS, the principle of inhibiting 
HSP90 is a very promising way of treating tumors. In this paper I have briefly demonstrated 
the effect of HSP90 inhibition in MLS cells and further investigated the mechanism of HSP90 
inhibition. A lot of questions remain and further experiments are needed to get a better 
overview of how HSP90 mediates its effect. 
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8. Populärvetenskaplig sammanfattning 
Cancer drabbar över 57 000 personer årligen i Sverige och är ett stort hälsoproblem i dagens 
samhälle. Det är den näst vanligaste dödsorsaken efter hjärtkärlsjukdomar och mellan var 
tredje och varannan person  kommer att drabbas av cancer under sin livstid (1, 2). Cancer är 
ett samlingsbegrepp för maligna (elakartade) tumörer, det vill säga celler som börjat tillväxa 
ohämmat. Dessa tumörer tillväxer lokalt, men kan även skicka ut så kallade metastaser 
(dottersvulster) som sprider sig till andra delar av kroppen. 
De vanligaste cancertyperna i vårt samhälle är bröstcancer, prostatacancer, lungcancer, olika 
hudcancrar och tjocktarmscancer. Alla dessa maligna tumörer hör till en grupp som heter 
epiteliala cancrar (carcinom). En mer ovanlig grupp av cancrar är maligna tumörer som utgår 
från mjukvävnad, så som muskler, brosk och fett. Den här gruppen kallas för sarkom. 
Sarkom utgör mindre än 1 % av alla maligna tumörer. Det vanligaste sarkomet heter 
Liposarkom och är en tumör som är rik på fettceller. Myxoid liposarkom är den vanligaste 
varianten av Liposarkom och kännetecknas av små fettliknande tumörceller som  ligger 
utspridda bland bindväv som ser slemaktig ut. ”Myxoid” kommer från grekiskan och betyder 
just ”slem”. 
De här tumörerna drabbar personer i medelåldern, tillväxer mycket långsamt och har en 
medelgod prognos. Femårsöverlevnaden efter diagnos ligger på i snitt 70 %, vilket kan 
jämföras med 90 % för bröstcancer och 6 % för bukspottskörtelcancer. Myxoida liposarkom 
behandlas främst med kirurgi och strålning. Mer aggressiva tumörer och tumörer som spritt 
sig i kroppen behandlas med cellgifter. Det finns tre cellgifter registrerade för Myxoida 
liposarkom, men inget av dem har särskilt god effekt. 
På senare år har en ny typ av cellgift kommit ut på marknaden. Det bygger på att hämma ett 
protein i kroppen som heter Heat shock protein 90 (HSP90). HSP90 är ett protein som är 
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viktigt för att cellerna ska hantera olika former av stress. Har cellerna producerat felaktiga 
proteiner på grund av till exempel överhettning eller giftiga ämnen (toxiner), så  hjälper 
HSP90 till att rätta till dem. I cancer kan dock tumörceller utnyttja det här systemet till att 
bibehålla signaler för celltillväxt som normalt inte ska vara aktiverade. 
En typ av proteiner som heter receptortyrosinkinaser kan mediera celltillväxtstimulerande 
signaler. Det finns en stor andel receptortyrosinkinaser i myxoida liposarkom och de anses 
vara en viktig tumördrivande faktor. Som ett försök att behandla myxoida liposarkom har man 
försökt att blockera dessa receptorer, men med föga resultat. Många receptortyosinkinaser är 
reglerade av HSP90 och försök i andra tumörer än Myxoida liposarkom har visat att 
receptortyrosinkinaser nedregleras av HSP90-hämning. 
Försök har visat att HSP90-hämning dödar tumörceller från myxoida liposarkom. Vi ville se 
om receptortyrosinkinaser nedreglerades även i myxoida liposarkom och om detta kan vara en 
orsak till att tumörcellerna dör. 
Vi har analyserat effekten på tumörceller i cellodling vid tillsats av HSP90-hämmaren 17-
DMAG. Vi har undersökt hur snabbt cellerna tillväxer med och utan 17-DMAG genom att 
odla dem i plattor som kontinuerligt registrerar cellantalet. Vi har registerat mängden av olika 
receptortyrosinkinaser med och utan 17-DMAG genom en metod som heter Western blot. Vi 
har dessutom försökt lokalisera var i cellerna receptortyrosinkinaserna är uttryckta genom en 
metod som heter immunofluorescens.  För att se ifall 17-DMAG orsakar några konsekvenser 
på gen-nivå har vi framställt prover som ska skickas på en stor screening av tumörernas gener. 
Genom att analysera detta hoppas vi hitta olika mönster av gener som förklarar varför olika 
tumörceller reagerar på olika sätt vid tillsats av 17-DMAG. 
Våra resultat visar att celler som har högt uttryck av receptortyrosinkinaser är extra känsliga 
för hämning av HSP90. Två av tre receptortyrosinkinaser som vi har analyserats nedregleras 
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vid tillsats av 17-DMAG. Dessutom verkar det som att man kan potentiera denna effekt 
genom att tillföra proteiner som aktiverar andra signaleringsvägar som regleras av HSP90, 
samtidigt som man tillför 17-DMAG. 
Icke-tumörceller innehåller väldigt små mängder av tyrosinkinaser. Det verkar inte som att 
dessa celler påverkas av 17-DMAG utan fortsätter att dela sig som vanligt, vilket är bra ur en 
biverkningssynpunkt. 
Detta indikerar på att uttryck av receptortyrosinkinaser är en nödvändig faktor för att 17-
DMAG ska ha effekt. Att hämma HSP90 minskar uttryck av receptortyrosinkinaser och dödar 
tumörceller. Hämning av HSP90  kan vara ett sätt att blockera tillväxten i 
receptortyrosinkinas-beroende tumörer som inte svarar på hämmare av receptortyrosinkinaser. 
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